Cover Image
市场调查报告书

Netupitant-Palonosetron FDC:全球的市场机会的评估

Netupitant - Palonosetron Fdc - Global Market Opportunity Assessment Study, 2012 - 2018

出版商 Transparency Market Research 商品编码 253511
出版日期 内容信息 英文 54 Pages
商品交期: 最快1-2个工作天内
价格
Back to Top
Netupitant-Palonosetron FDC:全球的市场机会的评估 Netupitant - Palonosetron Fdc - Global Market Opportunity Assessment Study, 2012 - 2018
出版日期: 2012年10月24日 内容信息: 英文 54 Pages
简介

全球化疗引起的恶心和呕吐(CINV)的市场由于高频率的癌症相关症状和患者人口的增加,到2015年为止将达到17亿美元的市场规模。全球CINV患者人口2015年预计将达到460万人,尤其是亚洲地区为最大规模的地区。因此亚洲市场的Netupitant-Palonosetron将有很大的潜在市场机会。

本报告提供Netupitant-Palonosetron FDC的市场机会调查分析,化疗诱发性恶心呕吐(CINV)概要,Netupitant-Palonosetron FDC概要,作用机制,临床试验数据,Netupitant-Palonosetron FDC的销售额预测及销售额的因素分析,全球授权契约趋势,再加上主要企业简介等汇整数据,为您概述为以下内容。

第1章 序文

第2章 摘要整理·市场概要

第3章 市场分析

  • 简介:化疗诱发性恶心呕吐(CINV)
    • 概要
    • CINV的病因/原因
    • 现在可以利用的药物治疗
  • CINV市场规模·市场机会方案
    • 全球CINV市场预测
    • CINV市场预测:各地区
    • 全球CINV患者数的预测
    • CINV标的患者数的预测:各地区
  • Netupitant-Palonosetron FDC概要
  • Netupitant-Palonosetron FDC的作用机制
  • 临床试验详细内容
    • 临床试验详细内容-1
      • 临床试验ID:NCT01376297
    • 临床试验详细内容-2
      • 临床试验ID:NCT01339260
  • CINV市场上未满足需求
  • Netupitant-Palonosetron FDC销售的因素
  • 销售预测:Netupitant-Palonosetron FDC
    • 全球标的患者数
    • 全球销售额预测
  • SWOT分析
    • 优点
    • 缺点
    • 市场机会
    • 威胁
  • Netupitant-Palonosetron FDC的授权合约
    • 全球
    • 美国
    • 欧洲
    • 澳洲
    • 英国·爱尔兰
    • 韩国
  • 企业简介:Helsinn Group
目录

Abstract

Description

This report covers Netupitant - Palonosetron FDC along with their sales projection, current scenario, SWOT analysis, clinical trials and opportunities. It also covers the factors driving this market and the regional analysis including United States, Europe, Australia and UK among others. The present market condition and performance has been mentioned in detail along with the CINV patient pool. Moreover, the report provides in-depth analysis of Netupitant - Palonosetron FDC market with their estimated and forecast market size till 2018.

The global Chemotherapy-induced nausea and vomiting (CINV) market is expected to reach USD 1.7 billion by 2015, due to prevalent cancer related conditions and subsequent increase in CINV pool. The global CINV patient pool is estimated to reach 4.6 million by 2015 and the Asian region is expected to witness largest patient share for CINV contributing majorly to the total CINV patient pool. Therefore, Asian market is expected have huge potential in the Netupitant - Palonosetron market.

We have used secondary research for deriving our market numbers for each segment of the research report and further validated our analysis with key opinion leaders. This research is specially designed to estimate and analyze the performance of Netupitant-Palonosetron FDC in global scenario. This research provides in-depth analysis of Netupitant-Palonosetron FDC market sales, trend analysis by segments and demand by geography. The in-depth research and high level analysis will allow Netupitant-Palonosetron FDC players to make informed decisions about Netupitant-Palonosetron FDC market in the present and future scenario.

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Research Methodology
    • 1.1.1. Therapeutic Classes
    • 1.1.2. Order of Entry into the Market
    • 1.1.3. Indications
    • 1.1.4. Dosage & Formulation Type
    • 1.1.1. Company Overview
    • 1.1.2. Business Strategy
    • 1.1.3. Financial Overview
    • 1.1.4. Products and Services
    • 1.1.5. Recent Developments

2. Executive Summary and Market Overview

3. Market Analysis

  • 3.1. Introduction: Chemotherapy Induced Nausea and Vomiting (CINV)
    • 3.1.1. Description
    • 3.1.2. Aetiology/Causes for CINV
    • 3.1.3. Current Drug Treatment Available
  • 3.2. CINV Market Size & Opportunity Scenario (1/2)
    • 3.2.1. Global CINV Market (USD Million), 2009 - 2015
    • 3.2.2. CINV Market (USD Million), by Geography, 2009 - 2015
    • 3.2.3. Global CINV Patient Pool (Million), 2009 - 2015
    • 3.2.4. CINV Target Patient Pool, by Geography, 2009 - 2015
  • 3.3. Description of Netupitant - Palonosetron FDC
  • 3.4. Mechanism of Action of Netupitant - Palonosetron FDC
  • 3.5. Clinical Trials Detail
    • 3.5.1. Clinical Trial Detail - 1
      • 3.5.1.1. Trials Id - NCT01376297
    • 3.5.2. Clinical Trial Detail - 2
    • 3.5.2.1. Trials Id - NCT01339260
  • 3.6. Unmet Needs in CINV Market
  • 3.7. Factors influential to the sales of Netupitant - Palonosetron FDC
  • 3.8. Sales Projection: Netupitant - Palonosetron FDC
    • 3.8.1. Global Target Patient Pool
    • 3.8.2. Global Forecasted Sales in $ in 000's
  • 3.9. SWOT Analysis
    • 3.9.1. Strength
    • 3.9.2. Weakness
    • 3.9.3. Opportunity
    • 3.9.4. Threat
  • 3.10. Overall License Agreement for Netupitant - Palonosetron FDC
    • 3.10.1. Global
    • 3.10.2. United States
    • 3.10.3. Europe
    • 3.10.4. Australia
    • 3.10.5. UK & Ireland
    • 3.10.6. South Korea
  • 3.11. Company Profile - Helsinn Group
Back to Top